The results of a previous study showed that the majority of patients with oligo-residual disease had PD limited to residual sites after EGFR-TKI treatment, providing a rationale for LAT of all disease sites in patients with EGFR-mutated NSCLC and oligo-residual disease. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.